Hyloris Pharmaceuticals SA
LSE:0AB6
Hyloris Pharmaceuticals SA
Hyloris Pharmaceuticals SA engages in the development and reformulating of pharmaceutical products. The company is headquartered in Liege, Liege and currently employs 14 full-time employees. The company went IPO on 2020-06-29. Its focus is on re-engineering cardiovascular products. Additionally, it also further develops and improves already-approved pharmaceuticals and established products, creating new and different solutions. The Company’s diverse product-development portfolio spans a wide range of therapeutic indications and dosage forms.
Hyloris Pharmaceuticals SA engages in the development and reformulating of pharmaceutical products. The company is headquartered in Liege, Liege and currently employs 14 full-time employees. The company went IPO on 2020-06-29. Its focus is on re-engineering cardiovascular products. Additionally, it also further develops and improves already-approved pharmaceuticals and established products, creating new and different solutions. The Company’s diverse product-development portfolio spans a wide range of therapeutic indications and dosage forms.